*Disclaimer

ANTERIS TECHNOLOGIES LTD (ASX: AVR)

🔗 📄 📈

AVR: Latest Patient Group Show Best Results to Date at 30 Days

ANTERIS TECHNOLOGIES LTD

2023-06-13 08:41:00

AVR: DurAVR THV Demonstrate Sustained Haemodynamics to 1 Year

ANTERIS TECHNOLOGIES LTD

2023-06-09 09:44:00

AVR: DurAVR Maintains Exceptional Results in New Patient Cohort

ANTERIS TECHNOLOGIES LTD

2023-05-31 09:52:00

AVR: FIH Results Presented at EuroPCR & Simultaneous Publication

ANTERIS TECHNOLOGIES LTD

2023-05-22 10:00:00

AVR: Additional Patent for Heart Valve Replacement Technology

ANTERIS TECHNOLOGIES LTD

2023-05-17 08:49:00

AVR: Agreement to Develop New Heart Valve Repair Device

ANTERIS TECHNOLOGIES LTD

2023-04-19 09:20:00

AVR: Patent for Transcatheter Heart Valve Replacement Technology

ANTERIS TECHNOLOGIES LTD

2023-04-12 09:08:00

AVR: Settlement of $35M Capital Raising Transaction

ANTERIS TECHNOLOGIES LTD

2023-02-15 10:46:00

AVR: FDA Grants Expanded Approval for the DurAVR EFS

ANTERIS TECHNOLOGIES LTD

2023-02-09 09:53:00

AVR: $35M Capital Raise

ANTERIS TECHNOLOGIES LTD

2023-02-09 09:52:00

AVR: Proposed $50 Million Capital Facility

ANTERIS TECHNOLOGIES LTD

2023-02-06 11:14:00

AVR: DurAVR First in Human Study 12 Month Results

ANTERIS TECHNOLOGIES LTD

  1. The DurAVR â„¢ Transcatheter Heart Valve (THV) First -in-Human Study met all performance endpoints with remarkable hemodynamic function sustained to 12 months.
  2. DurAVR â„¢ THV demonstrated an outstanding safety profile. All safety endpoints were met: No mortality (all causes), no disabling stroke, no life-threatening bleeding, and no myocardial infarction at 12 months.
  3. These encouraging preliminary First -in-Human study results will be further validated in an FDA-approved Early Feasibility Study (EFS) in early 2023.

2023-01-16 14:52:00